Physicians' Academy for Cardiovascular Education

Caffeine linked to lower risk of death in women with diabetes

EASD 2017 - Lisbon Portugal

Sep. 14, 2017 - news
 In NHANES data, regularly drinking caffeinated coffee or tea was associated with lower mortality risk in women with diabetes, the protective effect varied with the source of caffeine.

EASD 2017 In NHANES data, regularly drinking caffeinated coffee or tea was associated with lower mortality risk in women with diabetes, the protective effect varied with the source of caffeine.

Improved CV risk profile upon treatment with combination of insulin degludec/liraglutide in T2DM

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
A posthoc analysis of data of the DUAL II and DUAL V studies showed that T2DM patients treated with insulin degludec/liraglutide had reduced CV risk factors than those treated with insulin.

EASD 2017 A posthoc analysis of data of the DUAL II and DUAL V studies showed that T2DM patients treated with insulin degludec/liraglutide had reduced CV risk factors than those treated with insulin.

Cognitive behavioral group therapy not better at preventing weight regain after dieting in T2DM

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
Two years after dieting, T2DM patients in a cognitive behavioral group therapy program showed similar weight regain and CV risk factors as those receiving standard care.

EASD 2017 Two years after dieting, T2DM patients in a cognitive behavioral group therapy program showed similar weight regain and CV risk factors as those receiving standard care.

Room for improvement at risk factor management in transgender patients with diabetes

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
Despite management by a multidisciplinary team, transgender persons with diabetes treated with hormones for gender confirmation had modifiable risk factors that aggravate diabetes.

EASD 2017 Despite management by a multidisciplinary team, transgender persons with diabetes treated with hormones for gender confirmation had modifiable risk factors that aggravate diabetes.

New NHS device helps loose weight and improve glucose regulation in obese T2DM patients

EASD 2017 - Lisbon, Portugal

Sep. 13, 2017 - news
NHS provides the new, non-surgical, reversible weight loss Endobarrier device to help patients with poorly controlled T2DM and obesity kickstart a change in lifestyle.

EASD 2017 NHS provides the new, non-surgical, reversible weight loss Endobarrier device to help patients with poorly controlled T2DM and obesity kickstart a change in lifestyle.

Clinical benefit of SGTL2 inhibitor in T2DM with CVD independent from background glucose control

EASD 2017 - Lisbon, Portugal

Sep. 12, 2017 - news
Three subanalyses of EMPA-REG OUTCOME showed lower CV mortality risk in people with T2DM and established CV disease on empagliflozin treatment, irrespective of background blood sugar control.

EASD 2017 Subanalyses of EMPA-REG OUTCOME showed lower CV mortality risk in people with T2DM and established CV disease on empagliflozin treatment, irrespective of background blood sugar control.

Better long-term overall blood sugar control in type 1 diabetes with new fast-acting insulin

EASD 2017 - Lisbon, Portugal

Sep. 12, 2017 - news
A new-generation, ultra-fast acting mealtime insulin aspart improved HbA1c and postprandial glucose control over 52 weeks, compared to conventional insulin aspart in T1DM.

EASD 2017 A new-generation, ultra-fast acting mealtime insulin aspart improved HbA1c and postprandial glucose control over 52 weeks, compared to conventional insulin aspart in T1DM.

More glucose and weight reductions with once-weekly GLP-1 analogue vs. comparator treatments

EASD 2017 - Lisbon, Portugal

Sep. 12, 2017 - news
Post-hoc analysis of the SUSTAIN 1-5 trials shows that more adults with T2DM treated with semaglutide showed clinically meaningful reductions of HbA1c and body weight than those on comparator treatments.

EASD 2017 Post-hoc analysis of the SUSTAIN 1-5 trials shows that more adults with T2DM treated with semaglutide showed clinically meaningful reductions of HbA1c and body weight than those on comparator treatments.

Higher CV morbidity and mortality risk for hospitalized patients with T2DM and NAFLD

EASD 2017 - Lisbon, Portugal

Sep. 12, 2017 - news
Scottish population-based data reveal that hospitalized people with T2DM and non-alcoholic fatty liver disease have an increased risk of CVD events and CV and all-cause mortality.

EASD 2017 Scottish population-based data reveal that hospitalized people with T2DM and non-alcoholic fatty liver disease have an increased risk of CVD events and CV and all-cause mortality.

Well-conducted trial confirms principle that renal denervation can lower blood pressure

ESC 2017 - Barcelona

Aug. 29, 2017
The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.

ESC 2017 The SPYRAL-HTN study showed encouraging results with renal denervation in a sham-controlled trial. Blood pressure was reduced in patients not requiring medication for their hypertension.

Novel insights into causal pathways in type 2 diabetes

Sep. 11, 2017 - Liu J et al. - Diabetes 2017

Mendelian randomization provides evidence for possibly causal metabolic pathways of glucose homeostasis and T2DM, showing for instance that triglycerides and small HDL particles increase glucose.

Novel endovascular baroreflex-amplifying implant lowers BP in therapy-resistant hypertension

Sep. 11, 2017 - Spiering W et al., CALM-FIM_EUR investigators - Lancet. 2017

First-in-human study showed that MobiusHD device that amplifies the baroreflex lowered BP and the need for antihypertensive treatment for up to 6 months, with acceptable safety.